Are Serum Ferritin Levels a Reliable Cancer Biomarker?
The latest research from Panaxea International and Dr Daniel Weber contributes to our knowledge of ferritin as a cancer marker predictor.
Although serum ferritin (SF) has been shown in several studies to be a potential cancer biomarker, the results are inconsistent.
Herein, a systematic review was performed to investigate the clinical SF levels in different types of tumours in order to verify the role of SF levels as a biomarker for cancer diagnosis.
The search was performed using the PubMed/ Medline, Cochrane Library, and Scopus databases.
Observational studies comparing SF levels between healthy adults and patients with cancer were included.
The meta-analysis was carried out according to the inverse variance and random effects model.
The standardised mean differences (SMDs) were assessed at 95% confidence intervals (Cis).
The researchers found that SF was higher in patients with cancer (SMD 3.07; Ci 1.96,4.17), especially for head and neck cancer (SMD 3.88; Ci 0.42,7.34), lung cancer (SMD 1.72; Ci 0.67,2.78), pancreatic cancer (SMD 6.79; Ci 5.66,7.91), and renal cell carcinoma (SMD 1.77; Ci 0.48,3.05).
Moreover, in the advanced stages (Stages iii and iv), ferritin levels were higher than in healthy adults (SMD 4.89; Ci 2.72,7.06, and SMD 8.40; Ci 6.99,9.82, respectively).
SF acts as a biomarker for pancreatic cancer, renal cell carcinoma, lung cancer, and head and neck cancer and is a sensitive biomarker for the detection of advanced stages of tumours.
Are Serum Ferritin Levels a Reliable Cancer Biomarker? A Systematic Review and Meta-Analysis. Nutrition and Cancer. Sep 2021 https://doi.org/10.1080/01635581.2021.1982996.
|Tags:NewsEvidence Based ResearchCancer|